Latest News

FDA Accepts BLA Resubmission of Denileukin Diftitox for R/R CTCL
FDA Accepts BLA Resubmission of Denileukin Diftitox for R/R CTCL

March 18th 2024

If approved, denileukin diftitox could offer a valuable addition to the treatment landscape of relapsed/refractory cutaneous T-cell lymphoma.

FDA Lifts Clinical Hold on Trial of NX-2127 in B-Cell Malignancies
FDA Lifts Clinical Hold on Trial of NX-2127 in B-Cell Malignancies

March 11th 2024

GemCloBu: A New Conditioning Regimen for Aggressive Lymphomas
GemCloBu: A New Conditioning Regimen for Aggressive Lymphomas

March 9th 2024

FDA Approves Zanubrutinib and Obinutuzumab in R/R Follicular Lymphoma
FDA Approves Zanubrutinib and Obinutuzumab in R/R Follicular Lymphoma

March 7th 2024

Bispecific Antibodies Provide a New Tool in B-Cell Lymphoma Treatment
Bispecific Antibodies Provide a New Tool in B-Cell Lymphoma Treatment

March 3rd 2024

Video Series
Video Interviews
Podcasts

More News